Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06068361

Diagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach

Diagnostic Evaluation of Dementia with Lewy Bodies Using a Multimodal Approach: EEG, Cognitive, Biological and MRI Biomarkers

Status
Recruiting
Phase
Study type
Observational
Enrollment
130 (estimated)
Sponsor
Assistance Publique - Hôpitaux de Paris · Academic / Other
Sex
All
Age
55 Years – 85 Years
Healthy volunteers
Not accepted

Summary

Dementia with Lewy body disease (DLB) is the second leading cause of degenerative cognitive disorder after Alzheimer's disease (AD). Its variable clinical expression makes diagnosis difficult. To date, there is no validated DLB diagnostic biomarker, despite several biomarkers in development (EEG, MRI, biology). Studies have shown that an improvement in diagnostic performance could be obtained by combining different modalities biomarkers using machine learning. The aim of this research is to identify the best combination of multimodal biomarkers for the diagnosis of DLB (EEG, MRI, biology, cognitive scores), using a machine learning approach applied to a clinical cohort.

Detailed description

Study population: Observational prospective cohort study including over 24 months at the GHU AP-HP. Nord Lariboisière, Cognitive Neurology Center : 50 probable DLB patients, 50 AD patients, and 30 control subjects with subjective cognitive impairment but without any element in favor of neurodegenerative disorders. Total clinical dataset n= 130. Act : * 32-electrode EEG (resting state, passive auditory and active visual task). * 4 dry electrode EEG cap simultaneously with the 32-electrode EEG Expected results: Improved DLB diagnosis performance using a combination of multimodal biomarkers (EEG, cognitive scores, plasma, brain MRI).

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTEEG32-electrode EEG (resting state, passive auditory and active visual task) + simultaneous recording with a 4 dry electrode EEG cap

Timeline

Start date
2024-09-11
Primary completion
2027-09-01
Completion
2027-09-01
First posted
2023-10-05
Last updated
2025-03-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06068361. Inclusion in this directory is not an endorsement.